Trevi Therapeutics (TRVI) Retained Earnings (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Retained Earnings of -$190000.0 for Q1 2026, up 99.94% year-over-year from -$95030.4 in Q1 2025, and down 100.04% quarter-over-quarter from $512.8 million in Q4 2025.
Trevi Therapeutics (TRVI) Retained Earnings (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$190000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.94% year-over-year to -$190000.0; the TTM figure through Mar 2026 stood at -$190000.0 (up 99.94% YoY), while the FY2025 annual figure was $512.8 million, up 840509.84% from the prior year.
- Retained Earnings for Q1 2026 stood at -$190000.0, down from $512.8 million in the prior quarter.
- The five-year high for Retained Earnings was $512.8 million in Q4 2025, with the low at -$321.5 million in Q3 2025.
- The 5-year median for Retained Earnings is -$135000.0 (2022), against an average of -$7.0 million.
- Peak annual rise in Retained Earnings reached 840509.84% in 2025, while the deepest fall reached 368573.81% in 2025.
- Trevi Therapeutics' Retained Earnings stood at -$122000.0 in 2022, then sank by 195911.48% to -$239.1 million in 2023, then soared by 100.03% to $61000.0 in 2024, then surged by 840509.84% to $512.8 million in 2025, then plunged by 100.04% to -$190000.0 in 2026.
- Business Quant data shows TRVI's Retained Earnings at -$190000.0 in Q1 2026, $512.8 million in Q4 2025, and -$321.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 682.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 682.58 Mn |
| Mar 31, 2026 | -190,000.00 |
| Dec 31, 2025 | 512.77 Mn |
| Sep 30, 2025 | -321.49 Mn |
| Jun 30, 2025 | -309.69 Mn |
| Mar 31, 2025 | -297.39 Mn |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | -84,000.00 |
| Mar 31, 2024 | 322.37 Mn |
| Dec 31, 2023 | -239.13 Mn |
| Sep 30, 2023 | -231.31 Mn |
| Jun 30, 2023 | -248,000.00 |
| Mar 31, 2023 | 318.23 Mn |
| Dec 31, 2022 | -122,000.00 |
| Sep 30, 2022 | 314.67 Mn |
| Jun 30, 2022 | -135,000.00 |
| Mar 31, 2022 | -188.25 Mn |
| Dec 31, 2021 | -180.92 Mn |
| Sep 30, 2021 | -172.40 Mn |